These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36579812)

  • 41. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
    Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
    Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
    Weycker D; Li X; Figueredo J; Barron R; Tzivelekis S; Hagiwara M
    Support Care Cancer; 2016 May; 24(5):2309-2316. PubMed ID: 26607482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
    Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
    Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
    McBride A; Alrawashdh N; MacDonald K; Abraham I
    Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
    Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
    Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
    Wang CY; Park H; Heldermon CD; Vouri SM; Brown JD
    J Manag Care Spec Pharm; 2022 Jul; 28(7):795-802. PubMed ID: 35737859
    [No Abstract]   [Full Text] [Related]  

  • 52. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
    Ise M; Matsuda K; Shimura A; Masamoto Y; Kurokawa M
    Int J Hematol; 2021 Jun; 113(6):823-831. PubMed ID: 33738702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
    Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
    Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
    Blayney DW; Mohanlal R; Adamchuk H; Kirtbaya DV; Chen M; Du L; Ogenstad S; Ginn G; Huang L; Zhang Q
    JAMA Netw Open; 2022 Jan; 5(1):e2145446. PubMed ID: 35084480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
    Masuda N; Tokuda Y; Nakamura S; Shimazaki R; Ito Y; Tamura K
    Support Care Cancer; 2015 Oct; 23(10):2891-8. PubMed ID: 25733000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.